help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology, doi:10.1210/en.2006-0276
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Couse, J. F.
Right arrow Articles by Korach, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Couse, J. F.
Right arrow Articles by Korach, K. S.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*TESTOSTERONE
Endocrinology Vol. 147, No. 8 3666-3678
Copyright © 2006 by The Endocrine Society

The Intraovarian Actions of Estrogen Receptor-{alpha} Are Necessary to Repress the Formation of Morphological and Functional Leydig-Like Cells in the Female Gonad

John F. Couse, Mariana M. Yates, Karina F. Rodriguez, Jo Anne Johnson, Donald Poirier and Kenneth S. Korach

Receptor Biology Section, Laboratory of Reproductive and Developmental Toxicology (J.F.C., M.M.Y., K.F.R., K.S.K.), Laboratory of Experimental Pathology (J.A.J.), National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709; and Medicinal Chemistry Division (D.P.), Oncology and Molecular Endocrinology Research Center, Centre Hospitalier Universitaire de Quebec, Sainte-Foy, Quebec, Canada G1V 4G2

Address all correspondence and requests for reprints to: Dr. Kenneth S. Korach, Receptor Biology Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, MD B3-02, P.O. Box 12233, Research Triangle Park, North Carolina 27709. E-mail: korach{at}niehs.nih.gov.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The predisposition of the testis and ovary to primarily synthesize testosterone (T) and estradiol (E2), respectively, is due to gonadal-specific cell types that differentially express the various hydroxysteroid (17ß) dehydrogenase (HSD17B) isoforms. In testes, Leydig cells rely on LH stimulation to maintain expression of the type 3 (HSD17B3) isoform, which specifically converts androstenedione to T. In ovaries, thecal interstitial (TI) cells also rely on LH to induce androgen synthesis but lack HSD17B3 and therefore secrete androgens of low biological activity. Therefore, thecal cells may possess a mechanism to repress the Leydig cell phenotype and HSD17B3 expression. E2 is known to inhibit experimentally Leydig cell function and proliferation. In the current study, we provide evidence that E2 prevents the development of functional Leydig-like cells in the murine ovary and that this action is mediated by estrogen receptor (ER) {alpha}. ER{alpha}-null ({alpha}ERKO) female mice exhibit testis-like levels of Hsd17b3 expression in the ovaries and male-like levels of plasma T. Herein, we demonstrate that: 1) Hsd17b3 expression in {alpha}ERKO ovaries is a primary effect of the loss of intraovarian ER{alpha} actions; 2) {alpha}ERKO ovarian cells produce substantial levels of T in vitro, and this is blocked by a HSD17B3-specific inhibitor; 3) Hsd17b3 expression in {alpha}ERKO ovaries is LH regulated and localized to the secondary interstitial (SI)/TI cells; and 4) {alpha}ERKO SI/TI cells possess Leydig-like ultrastructural features. These data indicate that intraovarian ER{alpha} actions are required to repress Hsd17b3 expression in the ovary and may be important to maintaining a female phenotype in SI/TI cells.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
THE WELL-CONSERVED sexually dimorphic pattern of gonadal steroid hormone secretion in mammals is vital to the proper development and function of reproductive tissues and behaviors. The predisposition of the testis and ovary to primarily produce testosterone (T) and estradiol (E2), respectively, is due primarily to the development of gonadal-specific cell types that differentially express enzymes involved in the final stages of steroid hormone synthesis, namely isoforms of the hydroxysteroid (17ß) dehydrogenase (HSD17B) family (1, 2, 3). The gonads of both sexes possess the enzymatic capacity to convert C27 sterols (e.g. cholesterol) to C19 steroids, primarily dehydroepiandrosterone and androstenedione (A4), which have low biological activity but are precursors for conversion to the more biologically active steroids, T and E2. In mammalian males, the Leydig cells of the testes are especially proficient at reducing A4 to T because they specifically express the androgenic or type 3 (HSD17B3) isoform (2, 4, 5, 6, 7). Furthermore, because testes possess a relatively modest level of aromatase (CYP19A1), which converts A4 and T to estrone and E2, respectively, the latter androgen is allowed to accumulate and be secreted. In contrast, granulosa cells in adult female ovaries possess substantially high levels of CYP19A1 but lack HSD17B3 (1, 2, 8), thereby favoring aromatization of A4 to estrone rather than reduction to T. The accumulating estrone is then reduced to E2 by the estrogenic or type 1 (HSD17B1) isoform, which is highly expressed in the granulosa cells of growing follicles, as well as in the uterus, adrenals, and mammary gland (1).

The importance of sexual dimorphic expression of HSD17B1 and HSD17B3 in female and male gonads, respectively, is well appreciated yet poorly understood. This is especially true of the mechanisms that restrict HSD17B3 expression to testicular Leydig cells. Leydig cells constitutively express the LH receptor and rely on LH stimulation to maintain HSD17B3 expression and T synthesis (6, 9, 10). Thecal interstitial (TI) cells of the ovary, however, also constitutively possess LH receptor and rely on LH stimulation to maintain steroidogenesis (11, 12) but are limited to the secretion of C19 steroids of low biological activity because they lack HSD17B3 expression (13). This divergence between Leydig and TI cells, which are thought to arise from a common primordial cell during gonadal differentiation, suggests that the latter cell type either lacks an LH-stimulated transcription factor(s) specific to the induction of HSD17B3 expression or possesses a mechanism(s) to actively repress HSD17B3 expression. E2 has long been considered a leading candidate to fulfill this postulated inhibitory mechanism because it exists at significantly higher levels in ovaries than testes and inhibits Leydig cell function and proliferation in experimental studies (14, 15) but has received little investigative attention in this regard. However, our recent studies provide the first definitive evidence of E2-mediated repression of Hsd17b3 expression in the ovary and suggest that receptor-mediated actions of E2 may play an important physiological role during ovarian development and function. We have shown previously that the ovaries of estrogen receptor (ER)-{alpha}-null ({alpha}ERKO) mice exhibit testis-like levels of Hsd17b3 expression and male-like levels of plasma T (16). These findings are corroborated by a report that female mice null for CYP19A1 and therefore lacking endogenous E2 synthesis exhibit comparable ovarian Hsd17b3 expression that is abolished by exogenous E2 treatments (17). These data indicate that ligand-dependent ER{alpha} actions are fundamental to the repression of Hsd17b3 expression in the ovary. In the current study, we expand our description of this unique {alpha}ERKO ovarian phenotype by demonstrating that: 1) ectopic Hsd17b3 expression is fundamentally due to the loss of intraovarian ER{alpha} actions and not a secondary effect of the hypergonadotropism that follows the neuroendocrine loss of ER{alpha} functions, 2) ovarian HSD17B3 activity in {alpha}ERKO females is responsible for their characteristic male-like T burden, 3) Hsd17b3 expression in {alpha}ERKO ovaries exhibits a pattern of LH regulation comparable with that of Leydig cells in the testes, 4) ectopic Hsd17b3 expression in {alpha}ERKO ovaries is localized to the secondary interstitial (SI)/TI cells, and 5) these same cells exhibit ultrastructural features that are generally considered unique to Leydig cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals
The Animal Care and Use Committee of the National Institute of Environmental Health Sciences preapproved all procedures involving animals. Animals were maintained in plastic cages in a temperature-controlled room (21–22 C) under a 12-h light, 12-h dark schedule and given NIH 31 mouse chow and fresh water ad libitum. Wild-type (Esr1+/+) and {alpha}ERKO (Esr1–/–) mice were of the C57BL/6 strain and obtained from our colony at Taconic Farms (Germantown, NY). LH-CTP transgenic mice were a mixed background strain (C57BL/6 x CF-1) and obtained from our in-house colony established with breeders from the original colony at Case Western Reserve University (Cleveland, OH; as a gift from Dr. John H. Nilson). Compound hypogonadal Gnrhhpg/Esr1+/+ (wild-typehpg) or Gnrhhpg/Esr1–/– ({alpha}ERKOhpg) mice were obtained from our colony that was established by crossing heterozygous Gnrhhpg males (C3H/HeH x 101/H; The Jackson Laboratory, Bar Harbor, ME) with Esr1+/– females (C57BL/6) and maintained at Charles River Laboratories (Wilmington, MA). All animals were genotyped by PCR on DNA extracted from tail biopsies using the Wizard SV 96 Genomic DNA extraction kit (Promega, Madison, WI). The procedures for genotyping Esr1–/– (16) and LH-CTP (18) mice have been described previously. All potential Gnrhhpg mice were genotyped using a three-primer PCR scheme based on the original description of the mutant Gnrhhpg allele (19). This PCR method used the following common forward primer and two reverse primers to differentiate the wild-type and mutant Gnrh alleles: forward, 5'-ATGATGCTGCCCACAATCG (bp 2446–2464) to reverse, 5'-TCCCAGACAGGAGTGAAGTGC (bp 2847–2827). These primers flank the mutant breakpoint at bp 2700 and produce a 402-bp amplimer from a wild-type Gnrh allele and no amplimer from a mutant Gnrh allele because sequences homologous to the reverse primer are deleted, and the above forward primer paired with the following reverse primer 5'-TTTCTACTCTCTTGAAACAGGCAAATT, which is homologous to sequences 47 bp beyond the mutant breakpoint and therefore produces a 301-bp amplimer that is unique to the mutant Gnrhhpg allele. All PCR results were evaluated by agarose gel electrophoresis.

Animal treatments and tissue collection
All animals were 2–5 months of age at the time of use. Animals were killed via CO2 asphyxiation, and whole blood was immediately drawn from the inferior vena cava, mixed with heparin, and the plasma later separated by centrifugation; gonads were promptly removed, trimmed of surrounding tissue, and processed according to the intended downstream analysis (as described below). Two experiments required the treatment of animals with gonadotropins before tissue collection. In the first, animals were implanted (sc) with an Alzet osmotic pump (Durect Corp., Cupertino, CA) rated for drug delivery of 0.5 µl/h for 7 d. Pumps were filled with: 1) vehicle (0.85% saline), 2) purified human LH (hLH) at 0.83 IU/µl, or 3) recombinant human FSH (hFSH) at 0.83 IU/µl to provide a calculated delivery of 10 IU gonadotropin/d. Gonadal tissues were collected as described above on the morning of the 7th day. hLH and hFSH preparations were purchased from Dr. A. F. Parlow via the National Hormone and Peptide Program (Torrance, CA). In the second experiments involving gonadotropin treatment, animals were injected (sc) twice daily for 3 consecutive days with vehicle (0.85% saline) or 5 IU human choriogonadotropin (hCG) (Sigma, St. Louis, MO). Gonadal tissues were then collected as described above on the morning of the 6th day, approximately 1 h after the final treatment.

Granulosa-thecal cell isolation
Ovaries were immediately removed from adult wild-type and {alpha}ERKO females upon death by CO2 asphyxiation and pooled according to genotype in 100-mm cell culture dishes containing ice-cold M199 medium (Invitrogen, Carlsbad, CA). Granulosa cells were then expressed into the medium by manual puncture of the ovaries with a 25-gauge needle and by applying slight pressure with a sterile spatula. The suspended granulosa cells in the medium were then concentrated via centrifugation at 250 x g for 5 min at 4 C and washed two times in M199 medium; the pellets were stored at –70 C for later RNA isolation. The remaining ovarian fragments were considered to represent an enriched stromal/TI cell fraction and as such were washed several times in M199 medium and concentrated by centrifugation; the pellets were stored at –70 C for later RNA isolation.

RNA isolation and gene expression assays
Total RNA was isolated from snap-frozen tissues or cell pellets using TRIZOL reagent (Invitrogen) according to the manufacturer’s protocol. The concentration and integrity of all final preparations was calculated via an A260 reading using a Molecular Devices Spectramax (Sunnyvale, CA) spectrophotometer and agarose gel electrophoresis of a 1-µg aliquot.

Northern blots were generated from 20 µg total RNA per sample using NorthernMax formaldehyde-based reagents and BrightStar (Ambion, Austin, TX) positively charged nylon membrane according to the manufacturer’s protocol. Blots were sequentially probed, stripped, and reprobed for serial gene expression analyses using StripEZ (Ambion)-generated riboprobes and stripping reagents. Radiolabeled antisense riboprobes for Hsd17b3 (bp 363–729 of U66827) and Cyp17a1 (bp 522–932 of M4863) mRNAs were generated from previously described cDNA clones (16) using the StripEZ transcription reagents (Ambion) and [32P]{alpha}-UTP (Amersham Biosciences, Piscataway, NJ). Hybridizations were carried out in ULTRAhyb hybridization solution (Ambion) with approximately 1 x 107 cpm riboprobe/ml in a 68 C rotisserie oven (Thermo-Hybaid, Franklin, MA) and then washed according to the manufacturer’s protocol. Blots were exposed to a PhosphorImager screen, and the data were analyzed with a Storm 860 and accompanying ImageQuant Software (Molecular Dynamics, Sunnyvale, CA).

RT-PCR was carried out on total RNA that was first rid of contaminating DNA by use of the DNA-free reagents (Ambion) according to the manufacturer’s protocol. For each sample, cDNA was generated from 1 µg RNA in a 25-µl reaction using random hexamers and the Superscript cDNA synthesis system (Invitrogen) according to the manufacturer’s protocol. Traditional PCRs were then prepared from the equivalent of 1 µl cDNA per 15-µl reaction for each respective primer set using PCR reagents and Platinum Taq Polymerase (Invitrogen) as previously described. PCR was carried out in a Thermo Hybaid Multiblock System (Thermo-Hybaid) with the following cycling conditions: 95 C/30 sec (one time); 95 C/30 sec, 58 C/45 sec, and 72 C/30 sec (28–35 times); and 72 C/7 min. The primer sets for assessing Hsd17b3, Hsd17b1, and Actb mRNAs have been described previously (16). All samples were electrophoresed on an agarose gel (2% NuSieve/0.7% SeaKem, BMA Bioproducts, Rockland, ME) in 1x Tris-borate-EDTA buffer, stained with ethidium bromide, and photographed using an EC3 Imaging System (UVP, Upland, CA).

For real-time RT-PCR assessment of gene expression, Applied Biosystems Primer Express (Applied Biosystems, Foster City, CA) software was used to select primers specific for the amplification of murine Hsd17b1, Hsd17b3, Cyp17a1, and Cyp19a1 cDNAs (Table 1Go). All primer sets were: 1) designed to lie in separate exons to avoid erroneous amplification of contaminating genomic DNA, 2) confirmed to amplify a single product via dissociation analysis and gel electrophoresis, and 3) confirmed to amplify the expected sequences by restriction enzyme mapping of the amplified product. Each sample was assayed in duplicate using the equivalent of 0.01 µl cDNA (prepared as described above), 10 pmol of each primer, and 1x SYBR Green Master Mix (Applied Biosystems) in a total reaction volume of 25 µl. For normalization purposes, an identical set of reactions was prepared using primers specific for ribosomal 18S RNA (Rn18s) (Table 1Go). Amplification was carried out in an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) as follows: 50 C/2 min and 95 C/10 min (1 time) and 95 C/15 sec and 60 C/30 sec (40 times). Quantitative differences in the cDNA target between samples were determined using the mathematical model of Pfaffl (20) in which an expression ratio was determined for each sample by calculating (Etarget){Delta}Ct(target)/(ERn18s){Delta}Ct(Rn18s), where E is the efficiency of the primer set and {Delta}Ct = Ct(normalization cDNA) – Ct(experimental cDNA). The amplification efficiency of each primer set was calculated from the slope of a standard amplification curve of log microliters of cDNA per reaction vs. Ct value over at least 4 orders of magnitude (E = 10–(1/slope)); Hsd17b3 primers, E = 1.97 (vs. testis cDNA); Hsd17b1 primers, E = 2.02 (vs. ovary cDNA); Cyp17a1 primers, E = 2.16 (vs. ovary cDNA); and Cyp19a1 primers, E = 2.13 (vs. ovary cDNA).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Primers used for RT-PCR

 
In situ hybridization
Phylogeny Inc. (Columbus, OH) conducted all in situ hybridization experiments under paid contract. Gonadal tissues were collected from adult wild-type and {alpha}ERKO animals immediately upon death, fixed overnight in Phylogeny’s proprietary fixative, then dehydrated and infiltrated with paraffin. Serial sections of 5–8 µm were mounted on gelatin-coated slides, deparaffinized in xylene, and rehydrated through a series of graded ethanol baths in 1x PBS (pH 7.5). The sections were treated with proteinase K, then triethanolamine/acetic anhydride, washed, and dehydrated. Radiolabeled sense and antisense riboprobes for Hsd17b3 mRNA (bp 363–729 of U66827) were generated from a previously described cDNA clone (16) using Maxiscript reagents (Ambion) and 35S-{alpha}UTP (>1000 Ci/mmol; Amersham) according to the manufacturer’s protocol. Sections were hybridized overnight at 55 C in a solution of 50% deionized formamide, 0.3 M NaCl, 20 mM Tris-HCl (pH 7.4), 5 mM EDTA, 10 nM NaPO4, 10% dextran sulfate, 1x Denhardt’s, 50 µg/ml total yeast RNA, and radiolabeled riboprobe at 5–8 x 105 cpm/µl. The sections were then subjected to stringent washing at 65 C in a solution of 50% formamide and 2x sodium chloride/sodium citrate (SSC) buffer with 10 mM dithiothreitol and washed in 1x PBS, then treated with 20 µg/ml ribonuclease A at 37 C for 30 min. The slides were washed in 2x SSC and then 0.1x SSC for 10 min per wash at 37 C, dehydrated in a series of graded ethanol baths, dipped in Kodak NTB-2 nuclear track emulsion (Eastman Kodak, Rochester, NY), and exposed for 21 d in light-tight boxes with desiccant at 4 C. All slides were then developed in Kodak D-19, lightly counterstained with hematoxylin and eosin (H&E) and viewed and photographed under both light- and dark-field microscopy.

In vitro acute steroidogenic assays
The acute steroidogenic capacity of dispersed ovarian cells from wild-type, {alpha}ERKO, and LH-CTP animals was assessed in vitro using a method first described by Magoffin and Erickson (11, 21), with some modifications. In brief, ovaries were collected from five to six untreated or hCG-treated adult females of each genotype and pooled according to genotype and in vivo treatment in medium 199 with 100 mg/liter L-glutamine and 25 mm HEPES (M199; Invitrogen) on ice. The pooled ovaries were minced into eight to 10 pieces each, and the fragments were gently washed in M199. The ovarian fragments were incubated in M199 supplemented with 4 mg/ml collagenase (Sigma), 10 mg/ml deoxyribonuclease I (Sigma), and 10 mg/ml BSA (Sigma) at 37 C for 90 min in an ambient atmosphere. Several times during this incubation, the fragments were flushed through sterile pipettes with successively smaller orifices to obtain a preparation of dispersed cells. Each cell preparation was washed three times in M199, and the final cell pellet was suspended in 0.16 ml M199 per pair of ovaries in the original pool.

Acute steroidogenic assays were conducted in sterile 12 x 75 polystyrene culture tubes (BD Falcon, Bedford, MA). Each assay consisted of 25 µl dispersed ovarian cells in a 500-µl final volume of M199 supplemented with 10 IU/ml hCG or an equivalent volume of vehicle (0.85% saline) and/or a HSD17B3 inhibitor, 3ß-((N-cyclohexylmethyl-N-cyclopropylcarbonyl)aminomethyl)-3{alpha}-hydroxy-5{alpha}-androstan-17-one) (DP3-3), or equivalent volume of vehicle (100% ethanol). The generation and characterization of DP3-3 has been previously described (22) as compound 213 and was provided for these studies by D.P. All assays were prepared at a minimum of duplicate per genotype, per in vivo treatment, per in vitro treatment. Immediately after preparation, all assays were incubated for 4 h in a 37 C water bath in an ambient atmosphere. The cells were then pelleted by centrifugation at 8000 x g for 5 min, and the medium was transferred to a fresh tube and stored at –70 C for later analyses of A4 and T content by RIA. These experiments were repeated in three independent trials.

Hormone RIAs
Plasma and media androgen levels were assessed using the Active Androstenedione RIA and Active Testosterone RIA kits (Diagnostic Systems Laboratories, Webster, TX) according to the manufacturer’s protocol. All plasma hormone assays were performed in duplicate (when sample volume allowed) on samples collected from individual animals. All media hormone assays were performed on individual experimental samples and always in duplicate. Final assay samples were quantified using an Apex Automation {gamma}-Counter (Micromedic Systems, Seattle, WA) and accompanying software. For the A4 RIA, the least detectable concentration was 0.03 ng/µl, the average intraassay coefficient of variation was 2.5%, and the interassay coefficient of variation was 9.2%. For the T RIA, the least detectable concentration was 0.08 ng/µl, the average intraassay coefficient of variation was 3.0%, and the interassay coefficient of variation was 11.6%. RIAs on an equivalent volume of M199 supplemented with 10 IU/ml hCG or an equivalent volume of vehicle (0.85% saline) and/or 10 µM HSD17B3 inhibitor (DP3-3) or equivalent volume of vehicle (100% ethanol) indicated that the A4 and T content was below the level of detection for each steroid.

Transmission electron microscopy (TEM)
Adult animals were administered a sufficient dose of pentobarbital to induce deep anesthetization and then promptly perfused (whole body) with a modified Karnovsky’s fixative containing 2% paraformaldehyde and 2.5% glutaraldehyde, buffered to pH 7.4 in 0.1 M sodium cacodylate (Electron Microscopy Sciences, Hatfield, PA). Gonads were excised from the animals, placed whole in the above fixative for approximately 2 h, cut into 1–2-mm cubes, and then stored in the above fixative at 4 C until further processing. The tissues were then washed in 0.1 m sodium cacodylate, postfixed in 0.1 M sodium cacodylate-buffered 1% OsO4 (Electron Microscopy Sciences), rinsed in distilled water, dehydrated through a series of graded ethanol baths followed by propylene oxide, and embedded in Polybed epoxy resin (Polysciences, Warrington, PA). Ultrathin (90 nm) sections were prepared and stained on-grid with 5% uranyl acetate and Reynold’s lead citrate. All sections were examined in a FEI Tecnai 12 (Hillsboro, OR) transmission electron microscope operated at 80 kV and equipped with Microsoft Windows 2000 (Redmond, WA) and the MegaView III Soft Imaging System (Lakewood, CO). Several electron micrographs were taken for each sample to give an adequate sampling and representative overview.

Statistical analysis
All data were analyzed for statistical significance (P < 0.05) using JMP software (SAS Institute, Cary, NC). Data sets were first tested for homoscedasticity of variance using the Levene’s test and if failed were log-transformed before further statistical analysis. All data sets were then evaluated by a one-way ANOVA followed by the Tukey-Kramer honestly significant differences post hoc test when applicable.

The T to A4 (T/A4) ratios were calculated for each individual animal or in vitro assay sample using the formula first described by Weibe and Morris (23) to evaluate the endocrine profiles of women diagnosed with ovarian androgen excess. This value more effectively compares the degree of elevated T above normal (vs. a simple ratio) and employs the following formula: (plasma T/95% upper limit normal T)/(plasma A4/95% upper limit normal A4). For determining the in vivo T/A4 ratios (Fig. 1Go), the individual plasma levels from a group of adult wild-type female mice (n = 24) were used to determine the 95% upper limit for T and A4 as 0.10 and 0.25 ng/ml, respectively. For determining the in vitro T/A4 ratios (Figs. 5Go and 6Go), the acute in vitro steroid synthesis by dispersed cells from untreated wild-type ovaries (n = 3 replicates) was used to determine the 95% upper limit for T and A4 as 0.20 and 0.60 ng/ml, respectively.


Figure 1
View larger version (16K):
[in this window]
[in a new window]
  		FIG. 1. {alpha}ERKO females exhibit elevated plasma androgens. Shown are the average (±SEM) plasma levels for A4 (A) and T (B) in untreated adult wild-type (WT), {alpha}ERKO, and LH-CTP females and wild-type and {alpha}ERKO females treated twice daily with 5 IU hCG for 5 consecutive days (see Materials and Methods). Sample numbers (n) for each group were: wild-type, 24; wild-type + hCG, 22; {alpha}ERKO, 28; {alpha}ERKO + hCG, 8; and LH-CTP, 8. Bars that do not share the same letter are significantly different (P < 0.05). Bottom, Shown is the average T to A4 ratio for each genotype and treatment group as calculated using the formula of Weibe and Morris (23 ).

 

Figure 5
View larger version (28K):
[in this window]
[in a new window]
  		FIG. 5. In vitro evaluation of HSD17B3 activity in dispersed {alpha}ERKO ovarian cells. All data are from in vitro acute steroidogenic assays on dispersed ovarian cells (see Materials and Methods). These experiments were repeated three times and found to yield comparable results, shown are the results of one independent trial. Wild-type (WT) and {alpha}ERKO females were first treated twice daily for 3 d with vehicle or hCG as indicated along the x-axis; dispersed ovarian cells were then prepared from each genotype/treatment group and incubated for 4 h in the indicated in vitro treatments. A, In vitro A4 (top) and T (bottom) synthesis indicates that in vivo hCG treatments led to increased A4 production in both WT and {alpha}ERKO ovarian cells but increased T synthesis in {alpha}ERKO cells only. In vitro T synthesis in dispersed {alpha}ERKO ovarian cells was inhibited by the HSD17B3 inhibitor (DP3-3) at 10 µM. B, Shown is a dose-response curve illustrating the effect of the HSD17B3 inhibitor (DP3-3) on T synthesis in dispersed {alpha}ERKO ovarian cells. All data are from dispersed ovarian cells from untreated {alpha}ERKO females that were incubated in medium alone, medium with hCG (10 IU/ml), or medium with hCG (10 IU/ml) plus increasing concentrations of DP3-3. Each bar or point represents the average of three replicates, each of which was assayed in duplicate for each steroid. Bars that do not share the same letter are significantly different (P < 0.05). Significant differences (P < 0.05) within each genotype/treatment group are indicated by asterisks.

 

Figure 6
View larger version (41K):
[in this window]
[in a new window]
  		FIG. 6. In vitro evaluation of HSD17B3 activity in dispersed LH-CTP and {alpha}ERKO ovarian cells. All data are from in vitro acute steroidogenic assays on dispersed ovarian cells (see Materials and Methods). Dispersed ovarian cells were prepared from untreated adult LH-CTP and {alpha}ERKO females and incubated for 4 h in the indicated in vitro treatments. These experiments were repeated two times and found to yield comparable results; shown are the results of one independent trial. Although LH-CTP ovarian cells produce increased amounts of A4 relative to {alpha}ERKO ovarian cells, they produce much less T due to the absence of HSD17B3 activity. Bars that do not share the same letter are significantly different (P < 0.05). Significant differences (P < 0.05) within each genotype/treatment group are indicated by asterisks. Each bar represents the average of four ({alpha}ERKO) or three (LH-CTP) replicates, each of which was assayed in duplicate for each steroid.

 

   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
{alpha}ERKO females exhibit abnormally elevated plasma androgens
Adult {alpha}ERKO females possess levels of circulating A4 and T that are more than 3- and 50-fold that of wild-type females, respectively (Fig. 1Go). Wild-type females treated with hCG twice daily for 3 consecutive days exhibited significantly increased plasma androgen levels, but only A4 and not T approached the levels characteristic of {alpha}ERKO females (Fig. 1Go). Similar treatment of {alpha}ERKO females had no additive effect on plasma androgen levels. Female LH-CTP mice, a transgenic line that possesses chronically elevated LH levels that are more comparable with those of {alpha}ERKO females (16, 24), also exhibited significantly increased plasma A4 levels relative to wild-type and even {alpha}ERKO females, but much lower T levels compared with the latter genotype (Fig. 1Go). Therefore, {alpha}ERKO females largely differ from other models of ovarian LH hyperstimulation in their unique capacity to produce much greater levels of T. This male-like capacity of {alpha}ERKO ovaries to synthesize T is especially revealed when T/A4 ratios among the different genotypes are compared (Fig. 1Go). Wild-type females exhibited a T/A4 ratio of 0.82, which was significantly increased to 1.17 (P < 0.05) after 3 d of hCG treatment. Remarkably, LH-CTP females exhibited a similar T/A4 ratio (1.11) despite a life-long elevation in circulating LH. In contrast, {alpha}ERKO females exhibited a striking T/A4 ratio of 17.2 and showed no further increase after hCG treatment (17.0). These data indicate that chronic, excessive LH stimulation alone does not lead to male-like efficiency of T synthesis in murine ovaries but instead indicate that this phenotype is a primary effect of the loss of intraovarian ER{alpha}-mediated actions.

{alpha}ERKO ovaries exhibit testis-like expression and regulation of the Hsd17b3 gene
Comparative Northern blot analyses of gonadal RNAs indicated that {alpha}ERKO ovaries repeatedly possess levels of Hsd17b3 expression that are equal to or even greater than those observed in the testes of normal adult males, whereas levels in wild-type ovaries were below the level of detection (Fig. 2AGo). These data were confirmed by quantitative real-time RT-PCR, which indicated the level of Hsd17b3 expression in {alpha}ERKO ovaries was 2-fold that of adult testes (Fig. 2CGo). Similar analyses of LH-CTP ovaries also indicated a lack of Hsd17b3 expression but increased Cyp17a1 expression (Fig. 2Go, B and C), the latter being a known ovarian marker of LH stimulation. {alpha}ERKO ovaries also exhibited increased levels of Cyp17a1 expression that were 6- and 3-fold higher than those of wild-type and LH-CTP ovaries, respectively (Fig. 2CGo).


Figure 2
View larger version (29K):
[in this window]
[in a new window]
  		FIG. 2. Ectopic Hsd17b3 expression is unique to {alpha}ERKO ovaries. A, Northern blot analysis for Hsd17b3 transcripts in adult wild-type (WT) testes, WT ovaries, and {alpha}ERKO ovaries. The level of Hsd17b3 expression in adult {alpha}ERKO ovaries is comparable with that of WT testes but undetectable in WT ovaries. B, Northern blot analysis for Hsd17b3 transcripts in adult WT, {alpha}ERKO, and LH-CTP ovaries indicates that ectopic expression of Hsd17b3 does not occur in the ovaries of hypergonadotropic LH-CTP females. The same Northern blot was reprobed for Cyp17a1 transcripts, a known LH-regulated gene in the ovary. All Northern blots were probed for ribosomal Rn18s (18S rRNA) to demonstrate equal loading of total RNA among samples. C, Data from real-time RT-PCR (average ± SEM) for Hsd17b3 and Cyp17a1 expression in adult WT testes, WT ovaries, {alpha}ERKO ovaries, and LH-CTP ovaries. Hsd17b3 expression in {alpha}ERKO ovaries is 2-fold that of WT testes. {alpha}ERKO ovaries also exhibit significantly increased Cyp17a1 expression relative to WT testes and ovaries. Sample numbers (n) for each group were as follows: WT testes, three males; wild-type ovaries, five females; {alpha}ERKO, three females; and LH-CTP, three females. Bars that do not share the same letter are significantly different (P < 0.05).

 
Because LH is the principle hormone for the induction and maintenance of Hsd17b3 expression in Leydig cells of adult testes (25, 26, 27, 28), we sought to determine whether Hsd17b3 expression in {alpha}ERKO ovaries exhibits a similar, testis-like pattern of gonadotropin regulation. These experiments were conducted by treating hypogonadal (hpg) wild-type (wild-typehpg) and {alpha}ERKO ({alpha}ERKOhpg) females, which lack circulating endogenous gonadotropins, with a continuous infusion of exogenous hFSH or hLH for a period of 1 wk. Wild-typehpg males were similarly treated to provide data on the expected response in testes. As shown in Fig. 3Go, hLH increased Hsd17b3 expression almost 40-fold in the testes of wild-typehpg males, whereas the response to hFSH was measurable but conspicuously lower (<5-fold). Surprisingly, {alpha}ERKOhpg ovaries exhibited a similar response to hLH by increasing Hsd17b3 expression over 25-fold, whereas wild-typehpg ovaries exhibited a measurable but notably less robust increase in Hsd17b3 expression (Fig. 3Go). This difference in the induction of Hsd17b3 expression in the gonads of wild-type and {alpha}ERKO females is not due to a disparity in the effectiveness of hLH treatment because Cyp17a1, a known LH-induced gene, was increased 23- and 80-fold in each genotype, respectively (data not shown). hFSH treatment had no effect on Hsd17b3 expression in the ovaries of either genotype and only a minimal effect in the testes. However, the effectiveness of hFSH treatment in the ovaries of wild-type and {alpha}ERKO females was illustrated by induction of Hsd17b1 (Fig. 3Go), a known FSH regulated gene in the ovary (29, 30). FSH induced Hsd17b1 expression 4-fold in both wild-typehpg and {alpha}ERKOhpg ovaries, whereas LH had minimal effect (Fig. 3Go). Another known FSH-induced gene in the ovary, Cyp19a1, was also increased over 200-fold in both wild-type and {alpha}ERKO ovaries (data not shown). Neither gonadotropin induced Hsd17b1 expression in the testes of wild-typehpg males, demonstrating that this gene is distinctly expressed in ovaries.


Figure 3
View larger version (23K):
[in this window]
[in a new window]
  		FIG. 3. Gonadotropin induction of Hsd17b3 in hypogonadal {alpha}ERKO ovaries. Adult wild-typehpg (WThpg) males and females and {alpha}ERKOhpg females were treated for 1 wk with purified hLH or recombinant hFSH (see Materials and Methods). Top, Shown is a representative agarose gel of semiquantitative RT-PCR for Hsd17b3 and Hsd17b1 transcripts in the gonads of each genotype and treatment. Hsd17b3 expression is relatively unique to testes and maximally induced by hLH, whereas Hsd17b1 is relatively unique to ovaries and maximally induced by hFSH. Also apparent is the testis-like induction of Hsd17b3 expression in the ovaries of {alpha}ERKOhpg females. A small amount of Hsd17b3 expression is detectable by RT-PCR in the ovaries of LH-treated WThpg females. Bottom, Shown are the results of real-time RT-PCR quantitative assays (average ± SEM) for Hsd17b3 and Hsd17b1 transcripts in the gonads of each genotype and treatment. Sample numbers (n) for each group were: WThpg males (all groups), four per group; WThpg-none, two pools (three to four ovary pairs per pool); WThpg-hFSH, six; WThpg-hLH, three; and {alpha}ERKOhpg (all groups), two per group.

 
Ectopic Hsd17b3 expression occurs in the interstitial cells of {alpha}ERKO ovaries
To gain insight into the functional compartment responsible for ectopic Hsd17b3 expression in {alpha}ERKO ovaries, total RNA was prepared from ovaries that were first partitioned into fractions of enriched granulosa and stromal-interstitial cells. Northern blot analysis clearly indicated that Hsd17b3 mRNAs were concentrated in the stromal-interstitial compartment of {alpha}ERKO ovaries with only nominal detection in the granulosa cell fraction, most likely due to cross-contamination by small amounts of stromal material (Fig. 4Go). The relative purity of the fractions was illustrated by reprobing the blot for Cyp19a1 mRNAs, which are generally localized to granulosa cells of large follicles (Fig. 4Go).


Figure 4
View larger version (97K):
[in this window]
[in a new window]
  		FIG. 4. Northern blot and in situ hybridization (ISH) for Hsd17b3 mRNA in ovary and testes. Top left, Northern blot analysis on total RNA from pooled {alpha}ERKO ovaries that were fractionated into granulosa (GC) and stromal-interstitial (IC) cell compartments, demonstrating that Hsd17b3 expression in {alpha}ERKO ovaries is localized to the stromal-interstitial compartment. The blot was stripped and reprobed for transcripts of a granulosa cell-specific gene (Cyp19a1) to indicate the cellular purity of each ovarian fraction. A photograph of ethidium-stained Rn18s (18S rRNA) bands demonstrates equal loading levels between lanes. Top right, Cross-sections from representative adult wild-type and {alpha}ERKO ovaries photographed at low magnification. The WT ovary exhibits several healthy, large follicles (F) and a normal stromal-interstitial region (IC). In contrast, the {alpha}ERKO ovary exhibits some smaller, relatively healthy follicles (F) but several enlarged, cystic follicles (CF). Also indicated in the {alpha}ERKO ovary is a region of hypertrophied thecal cells (TC). Middle bottom, Shown are representative photomicrographs (bf, bright-field photomicrograph; df, dark-field photomicrograph) of tissue sections from wild-type testes, wild-type ovaries, and {alpha}ERKO ovaries (as labeled) that were subjected to ISH for Hsd17b3 mRNAs. Wild-type testis, Photomicrographs of serial sections from a representative adult wild-type testis show specific hybridization of the Hsd17b3 probe to the Leydig cells (LC) only, whereas hybridization levels among cells within the seminiferous tubules (ST), as indicated by dashed border, are at or below background. Wild-type ovary, Photomicrographs of serial sections from a representative wild-type ovary indicate no specific hybridization of the Hsd17b3 probe in the oocyte (O), granulosa (GC), SI (SIC), thecal (TC) cells, or any other cell type. Follicles are indicated by a dashed border. {alpha}ERKO ovary, Photomicrographs of a pair of serial sections from two representative {alpha}ERKO ovaries indicates specific hybridization of the Hsd17b3 probe to the SI cells (SIC) of the ovary, whereas hybridization levels among the granulosa cells of normal and cystic follicles (CF) are at or below background. Follicles are indicated by dashed border. Wild-typehpg testis, Dark-field photomicrographs of testes sections from WThpg males after treatment with either vehicle (–hCG) or hCG (+hCG) to induce Hsd17b3 expression in the Leydig cells (see Materials and Methods). The untreated WThpg testis exhibits little detectable Hsd17b3 mRNA, whereas the testis of the hCG-treated WThpg male exhibits significant induction of Hsd17b3 expression that is localized to the interstitial areas where Leydig cells (LC) are found. Seminiferous tubules are indicated by a dashed border. Controls, wild-type testis, Photomicrographs of serial sections from a WT testis probed with either the Hsd17b3 sense (negative control) or antisense (positive control) probes to illustrate specific hybridization of the antisense probe only to the Leydig cells (LC), as indicated by the numerous silver grains (arrow).

 
The above findings were further supported by in situ hybridization analyses of adult {alpha}ERKO ovaries. As shown in Fig. 4Go, Hsd17b3 mRNAs were distinctly localized to the stromal-interstitial regions of {alpha}ERKO ovaries, whereas hybridization levels were below background in the granulosa cells of follicles of all sizes. More precisely, Hsd17b3 expression in {alpha}ERKO ovaries was concentrated in the SI cells, which populate the areas between the follicles and medullary portions of the ovary. SI cells are thought to have once been TI cells, but after follicle atresia, they become no longer associated with growing follicles and populate the ovarian stroma (11). Because growing follicles in {alpha}ERKO ovaries characteristically exhibit poorly organized layers of TI cells, whether Hsd17b3 expression was distinct to the SI or shared between the two interstitial cell types was difficult to discern. No substantial hybridization of the Hsd17b3 probe was observed among any cell types in wild-type ovaries (Fig. 4Go). As expected, parallel experiments in testes from adult wild-type males indicated significant Hsd17b3 expression that was distinctly localized to Leydig cells (Fig. 4Go). Furthermore, hCG-mediated induction of Hsd17b3 expression in the testis of an adult wild-typehpg male was again specifically localized to the interstitial (extratubular) compartments of the testis where Leydig cells are located.

Ectopic HSD17B3 activity mediates T synthesis in {alpha}ERKO ovaries
Adult wild-type and {alpha}ERKO females were first treated with vehicle or hCG for 3 d to stimulate ovarian androgen production in vivo. Dispersed ovarian cell preparations were then generated, and their acute steroidogenic capacity was assessed during a 4-h in vitro incubation in the presence or absence of hCG and/or a HSD17B3 inhibitor (DP3-3). The results of these experiments are summarized in Fig. 5Go. As expected, {alpha}ERKO ovarian cells produced significantly more A4 and T compared with wild-type cells, regardless of in vivo or in vitro hCG exposure (Fig. 5AGo). In vivo hCG treatments enhanced in vitro A4 and T synthesis in both genotypes; however, only {alpha}ERKO ovarian cells exhibited an additive increase in overall androgen synthesis during in vitro hCG exposure. More importantly, these experiments provided two critical findings. First, consistent with the in vivo phenotype, T was clearly the predominant androgen produced by {alpha}ERKO ovarian cells in vitro, yielding an average T/A4 ratio of 3.32 ± 0.5 vs. 0.47 ± 0.1 in wild-type cells (untreated both in vivo and in vitro). Secondly, inclusion of the HSD17B3-specific inhibitor (DP3-3) consistently reduced T synthesis by 50–60% in {alpha}ERKO ovarian cells and decreased the average T/A4 ratio to 0.73 ± 0.2, providing strong evidence that T synthesis in {alpha}ERKO ovaries is largely due to ectopic HSD17B3 activity. In contrast, the minimal but detectable T synthesis by wild-type cells was not affected by the HSD17B3 inhibitor (T/A4 ratio = 0.45 ± 0.02), indicating that it is likely mediated by the androgenic activity of rodent HSD17B1, which is innate to ovarian granulosa cells. A representative dose-response curve for HSD17B3 inhibition of T synthesis by {alpha}ERKO ovarian cells in vitro is shown in Fig. 5BGo.

Similar experiments were conducted to compare the steroidogenic capacity of dispersed ovarian cells from LH-CTP and {alpha}ERKO females because these two models are more comparable in terms of chronic LH hyperstimulation of the ovary. Acute in vitro steroidogenic assays on dispersed cells from LH-CTP ovaries indicated substantial A4 production that was 2-fold that observed in {alpha}ERKO ovarian cells (Fig. 6Go), consistent with their in vivo androgen profile (Fig. 1Go). Only when {alpha}ERKO females were treated with exogenous hCG before tissue collection did the in vitro level of A4 synthesis become comparable with that of LH-CTP cells. This overabundance of A4 in LH-CTP cells is indicative of the increased Cyp17a1 expression shown earlier (Fig. 2Go). Still, even the highest level of in vitro A4 synthesis achieved in LH-CTP cells did not provide for {alpha}ERKO-like levels of T production, which were 3-fold higher in the latter genotype. Furthermore, the HSD17B3 inhibitor had no measurable effect on T synthesis in LH-CTP cells, indicating it is likely mediated by the androgenic activity of HSD17B1.

{alpha}ERKO ovaries harbor stromal Leydig-like cells
To determine whether the interstitial portions of {alpha}ERKO ovaries possessed Leydig-like ultrastructural features, we employed TEM to compare normal Leydig cells of mouse testes with stromal-interstitial cells of adult {alpha}ERKO ovaries. The typical whorl-arranged smooth endoplasmic reticulum (SER) that is innate to Leydig cells of mouse testes (31) is illustrated in Fig. 7Go, A and B. The Leydig cell shown possesses multiple whorls of SER, one of which surrounds a lipid droplet. Also prominent are random tubular SER and numerous mitochondria, the latter possessing the tubular cristae that are characteristic of steroidogenic cells (Fig. 7BGo) (31). Remarkably, a parallel survey of stromal-interstitial regions of multiple {alpha}ERKO ovaries identified cells that possessed similarly arranged SER, clearly organized as whorls and interspersed with large lipid droplets and tubular SER (Fig. 7Go, C–E). The whorl-like SERs found in {alpha}ERKO ovarian stroma-interstitial cells usually occupied a smaller intracellular area and were less structured relative to that in testicular Leydig cells (Fig. 7Go, C and D) but were clearly Leydig-like in appearance. In addition, the whorled SERs observed among {alpha}ERKO ovarian stromal-interstitial cells were often vesiculated (Fig. 7FGo), remarkably similar to that which occurs during the natural involution of Leydig cells in fetal or aged testes. These vesiculated structures in {alpha}ERKO ovarian stromal-interstitial cells are likely sites of lipid degradation and may account for the substantial intracellular prevalence of lipofuscin observed in H&E-stained tissue sections (Fig. 7HGo), which is also a common cytoplasmic component of Leydig cells in multiple species (31). Furthermore, the cells possessing Leydig-like SER and lipofuscin were limited to the interstitial regions in {alpha}ERKO ovaries, the normal site of SI cells and correlating with the areas of Hsd17b3 expression indicated by in situ hybridization. No similar structures were found in wild-type ovaries (data not shown).


Figure 7
View larger version (79K):
[in this window]
[in a new window]
  		FIG. 7. TEM indicates SI cells with Leydig-like ultrastructural features in {alpha}ERKO ovaries. Wild-type testes, A, representative Leydig cell in a wild-type testis possesses three clusters of whorled SER (wSER); B, higher magnification of A (indicated by outlined area) illustrates a wSER and two juxtaposed mitochondria (M) with tubular cristae that are characteristic of testicular Leydig cells. {alpha}ERKO ovary, C and D, representative examples of Leydig-like wSER found in the SI/TI cells of {alpha}ERKO ovaries. Numerous electron-dense lipid droplets (L) are surrounded by the wSER; tubular SER (tSER) that is typical of ovarian steroidogenic cells is also present. E, Shown is a higher magnification of D (indicated by outlined area). F, Shown is an example of vesiculated wSER in a {alpha}ERKO ovary. G, SI cell in a {alpha}ERKO ovary containing wSER with multiple large crystalline (Cr) inclusions throughout the cytoplasm. H, Photomicrograph of the follicle wall of a cystic follicle in a {alpha}ERKO ovary section stained with H&E, illustrating the considerable accumulation of lipofuscin (brown-pigmented material) in the cytoplasmic vacuoles among the SI cells.

 
Along with the above findings, TEM revealed an additional noteworthy characteristic of {alpha}ERKO ovarian SI cells. As illustrated in Fig. 7Go, C and G, numerous crystalline-like cytoplasmic inclusions were found to repeatedly coexist in cells that harbored whorled, Leydig-like SER. These inclusions were long, cylindrical bodies of 0.1–2 µm in length that were often present in great numbers and almost always associated with whorled SER. Crystalline cytoplasmic inclusions are a common feature of normal Leydig cells in the testes of several species and are considered a definitive attribute of human Leydig cells and Leydig cell tumors, within which they are referred to as crystals of Reinke (31). However, there are no reports of similar cytoplasmic crystalline inclusions in Leydig cells or ovarian SI cells of mice.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The collective findings from studies as early as the mid 1970s impart a convincing argument for an inhibitory role of estrogens on Leydig cell development, differentiation, and function (for review, see Ref. 14). For example, estrogens are documented to inhibit T synthesis in adult rodent Leydig cells (14) as well as disrupt Leydig cell proliferation and differentiation in fetal and neonatal testes (32). Furthermore, E2 inhibits the natural regeneration of Leydig cells that occurs in rodent testes after their destruction by acute exposure to ethane dimethylsulfonate, a Leydig cell-specific toxicant (33). In addition, the precisely timed periods of substantial Leydig cell proliferation and differentiation during testis development correlate inversely with periods of low endogenous E2 levels (15). Remarkably, the concept that these findings might reveal a parallel, physiological role for E2-mediated suppression of Leydig cell differentiation and T synthesis in ovaries has received little attention. Herein, we provide definitive evidence that E2 is principally involved in preventing the development of functional Leydig-like cells in the stromal-interstitial portions of the mouse ovary and that these actions are exclusively mediated by ER{alpha}.

Our assertion that {alpha}ERKO ovaries inappropriately possess functional Leydig-like cells is based on their exhibiting traits that are regarded as exclusive to testicular Leydig cells, including: 1) substantial Hsd17b3 expression and enzymatic activity, 2) whorl-like SER, and 3) crystalline-like structures comparable with crystals of Reinke. Furthermore, the ectopic Hsd17b3 expression in {alpha}ERKO ovaries is LH dependent and thus exhibits a pattern of gonadotropin regulation that is comparable with that of mature testicular Leydig cells. Similar Hsd17b3 expression and cells possessing Leydig-like features are reportedly present in the ovaries of mice lacking endogenous E2 due to targeted disruption of the Cyp19a1 gene, and the former phenotype is abolished by exogenous E2 treatments (17). However, because E2 treatment of CYP19A1-null females also results in normalization of the heightened LH levels that are present in these animals (17), these experiments do not discern whether the loss of ovarian Hsd17b3 expression is due to activation of intraovarian ER{alpha} or decreased gonadotropin stimulation. In the current study, we provide definitive evidence that ectopic Hsd17b3 expression in {alpha}ERKO females is due solely to the loss of ER{alpha}-mediated actions within the ovary and simply requires LH stimulation to manifest. For example, the ovaries of transgenic LH-CTP female mice categorically lack Hsd17b3 expression and activity (18 and Figs. 2Go and 6Go herein) despite being chronically exposed to substantially high levels of circulating LH (34, 35). The ovaries of ERß-null female mice also lack ectopic Hsd17b3 expression (16) even when harboring the LH-CTP transgene to increase circulating LH levels (18). Likewise, reports of transgenic mice that constitutively express hCG, an LH analog, describe ovaries exhibiting TI cell hypertrophy but make no reference to Hsd17b3 expression or Leydig-like cells (36, 37). In contrast, Heikkilä et al. (38) recently reported that the ovaries of newborn Wnt4-null female mice exhibit ectopic induction of Hsd17b3 expression that is concurrent with an 8-fold reduction in ER{alpha} expression but no change in ERß levels. All of these findings support our conclusion that ER{alpha} is critical to repressing the expression of this Leydig cell-specific steroidogenic gene in the ovary.

Evidence supporting the presence of substantial HSD17B3 enzymatic activities in {alpha}ERKO ovaries was revealed by several findings. Foremost was the remarkably high T/A4 ratio in the plasma of adult {alpha}ERKO females that is more comparable with that of normal male mice (39, 40) and adult men (41) as well as women clinically diagnosed with ovarian androgen excess (23). We have shown previously that increased androgen levels in {alpha}ERKO females are at least partially due to hyperstimulation of the ovary by LH (16). Still, when wild-type female mice were forced to possess a comparable hypergonadotropic condition via either daily injections with hCG, an LH analog, or transgenic methods, as achieved in LH-CTP mice, the resulting androgenic phenotype was markedly less severe and qualitatively different from that of {alpha}ERKO females because A4, and not T, was the predominant steroid produced in the former models. Secondly, we conducted specific experiments to discern the individual contributions of type 1 and type 3 activities to the overall T load in {alpha}ERKO females. This was necessary because the rodent ortholog of HSD17B1, which is normally expressed in the ovary and mediates the reduction of estrone to E2 (2, 42, 43), is equally efficient at reducing A4 to T (44, 45). Furthermore, Hsd17b1 expression is increased almost 2-fold above normal in {alpha}ERKO ovaries (16). By employing a method first described by Magoffin and Erickson (21, 46) that allows for the evaluation of the acute steroidogenic capacity of dispersed ovarian cells in vitro with the use of a specific inhibitor of HSD17B3 enzymatic activities (22), we were able to successfully discriminate type 1- and type 3-mediated HSD17B T synthesis in dispersed wild-type and {alpha}ERKO ovarian cells. The resulting data strongly indicated that the male-like capacity for T synthesis in {alpha}ERKO ovaries is due predominantly to the presence of substantial HSD17B3 activities, whereas the minimal level of T synthesis observed in hCG-treated wild-type or LH-CTP ovaries is due to the androgenic activities of HSD17B1 that occur in the presence of increased A4. T synthesis in {alpha}ERKO females is undoubtedly further promoted by a parallel increase in CYP17A1 activities that provide for ample synthesis of A4, the substrate for HSD17B3.

The mechanisms by which ER{alpha} actions suppress the testicular pathway of T synthesis in the ovary are unclear. Ligand-activated ER{alpha} may act in a dynamic manner within TI/SI cells to persistently inhibit Hsd17b3 expression. ER{alpha} is indeed amply expressed in both testicular Leydig cells (47, 48) and ovarian TI/SI cells (49, 50, 51). Furthermore, estrogens are known to inhibit T synthesis in both thecal and Leydig cells in vitro, although most evidence indicates that the upstream steroidogenic enzyme, CYP17A1, is the primary target (11, 14, 52). Indeed, CYP17A1 expression and activity are also increased in the ovaries (Fig. 2Go) (16), in vitro cultured follicles (Taniguchi, F., J. F. Couse, and K. S. Korach, unpublished data) and testes (53) of {alpha}ERKO but not ßERKO mice. However, ours is the first study to demonstrate that ER{alpha} represses ovarian T synthesis via robust negative modulation of Hsd17b3 expression as well. Interestingly, a recent report that {alpha}ERKO males exhibit a 2-fold increase in Hsd17b3 expression and type 3 activity (53) indicates that ER{alpha} may play an analogous role in testes.

In contrast to the above-postulated dynamic mechanism for ER{alpha}-mediated inhibition of Hsd17b3 expression and T synthesis in the ovary is a potential organizational role by which ER{alpha} might repress the development of a Leydig cell phenotype among the SI/TI cells. Support for such an organizational role for ER action during gonadal differentiation comes from multiple descriptions of permanently disrupted Leydig cell function in adult rodents after developmental exposure to estrogens as well as estrogen-mediated inhibition of Leydig cell regeneration and proliferation in ethane dimethylsulfonate-exposed testis (14). Herein, we employed TEM to produce evidence of Leydig-like cells in {alpha}ERKO ovaries. The "single most identifying characteristic of the Leydig cell" is their unique and often species-specific arrangements of SER (31). The Leydig cells of adult mouse testes, as well as other species, characteristically exhibit a portion of SER that is arranged as whorls often surrounding a lysosome or lipid droplet (Ref. 31 and references therein). This swirled form of SER is continuous with the tubular form and may comprise up to 7% of the total SER within a single Leydig cell (31). In the current study, we found that {alpha}ERKO ovaries possess SI cells that exhibit similar whorl-arranged SER as well as other Leydig cell features, including crystalline-like cytoplasmic inclusions and an accumulation of lipofuscin. Furthermore, the {alpha}ERKO ovarian cells exhibiting these Leydig-like features were located in the same ovarian regions that possessed significant levels of Hsd17b3 expression as indicated by in situ hybridization. These findings raise the prospect that a loss of ER{alpha} actions during SI/TI cell differentiation in the ovary may allow for the inappropriate development of cells possessing a Leydig-like phenotype. The capacity of adult hypogonadal {alpha}ERKO ({alpha}ERKOhpg) ovaries to rapidly acquire Hsd17b3 expression after acute exogenous hLH treatment suggests that the Leydig-like cells may develop in an environment void of gonadotropins and are present as early as birth or before puberty.

Our finding that the Leydig-like cells in adult {alpha}ERKO ovaries were located in the stroma and often bordered by SI/TI cells distinguishes them from hilar interstitial (HI) cells, which are natural to the ovary and considered structurally and functionally similar to testicular Leydig cells (11). HI cells are normally limited to the connective tissues in the hilus of the ovary (11), whereas the Leydig-like cells observed in {alpha}ERKO ovaries are located in the stroma, surrounded by TI/SI cells and usually in close proximity to a follicle. Admittedly, poor organization of the medullary regions is characteristic of adult {alpha}ERKO ovaries (54, 55) and may have altered the natural position of HI cells. Still, there is no evidence of Hsd17b3 expression in the HI cells of normal ovaries (8, 11), providing further evidence that the Leydig-like cells in {alpha}ERKO ovaries are not of hilar origin.

The stromal location of the Leydig-like cells in {alpha}ERKO ovaries in conjunction with their close proximity to hypertrophied SI/TI cells suggests that they may have once been part of the latter cell population but have since acquired a male-like phenotype via trans-differentiation. This phenomenon is thought to underlie the formation of stromal-Leydig cell tumors and nonhilar, pure Leydig cell tumors in women (56, 57). Although extremely rare, these ovarian tumors are invariably androgenic and often bordered by hypertrophied ovarian stroma (56, 57, 58, 59). Furthermore, there are clinical reports of HSD17B3-like activity in the ovaries of women suffering from ovarian androgen excess (60, 61), androgenic HSD17B immunoreactivity in a pure Leydig cell tumor (62), and HSD17B3 transcripts in a Sertoli-Leydig cell tumor and surrounding luteinized thecal tissue (63). In contrast, ovarian tissue and cell lines from women diagnosed with polycystic ovarian syndrome have been found to lack detectable HSD17B3 expression (64, 65, 66), indicating that this malady is not likely related to the ER{alpha}-null phenotype described here.

Thecal cell androgen synthesis is critical to ovarian function because androgens serve as both important hormonal signals during granulosa cell differentiation in the early stages of folliculogenesis and later as substrates for E2 synthesis in mature preovulatory follicles (67). However, when androgen levels and activity are allowed to surpass that required to support E2 synthesis during the latter stages of folliculogenesis, the follicle invariably becomes atretic (68, 69). This condition is likely exacerbated if T, rather than A4, is the predominant androgen present because the former steroid is a more potent androgen receptor agonist. Therefore, stringent regulation of the quantity and nature of TI/SI cell androgen synthesis is critical to the generation of healthy follicles capable of ovulation and fertilization. Our data provide strong evidence that ligand-dependent ER{alpha} actions are fundamental to this physiology of TI/SI cells by repressing their acquisition of HSD17B3 activities and perhaps their differentiation to a Leydig-like phenotype. Our description of ectopic Hsd17b3 expression and Leydig-like cells in the ovaries of ER{alpha}-null female mice represents the first data to support an integral intraovarian role for ER{alpha}. Further studies are required to discern whether ER{alpha} operates via activational or organizational mechanisms to repress the acquisition of a testis-like phenotype in the SI/TI cells of the ovary. A similar phenotype of granulosa to Sertoli cell trans-differentiation occurs in the ovaries of compound ER-null (ER{alpha}-null; ERß-null) female mice (70, 71). From these collective data, we may infer that ER-mediated E2 signaling is critical to the development and/or maintenance of the female phenotype in the endocrine somatic cell types of the ovary.


   Acknowledgments
 
We are grateful to numerous colleagues who have supported our efforts over the course of these studies, including Linwood Koonce and Vickie Walker for animal handling and breeding, Dr. John H. Nilson for providing LH-CTP breeder mice, Ralph Wilson for generously allowing the use of his {gamma}-counter, Dr. Abraham Nyska for consultation on pathology issues, and Drs. E. Mitch Eddy and William Schrader for their careful review of the manuscript.


   Footnotes
 
This work was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences.

J.F.C., M.M.Y., K.F.R., J.A.J., D.P., and K.S.K. have nothing to declare.

First Published Online April 20, 2006

Abbreviations: A4, Androstenedione; DP3-3, 3ß-((N-cyclohexylmethyl-N-cyclopropylcarbonyl)aminomethyl)-3{alpha}-hydroxy-5{alpha}-androstan-17-one); E2, estradiol; ER, estrogen receptor; {alpha}ERKO, ER{alpha}-null; hCG, human choriogonadotropin; hFSH, human FSH; H&E, hematoxylin and eosin; HI, hilar interstitial; hLH, human LH; HSD17B, hydroxy-steroid (17ß) dehydrogenase; SER, smooth endoplasmic reticulum; SI, secondary interstitial; SSC, sodium chloride/sodium citrate; T, testosterone; TEM, transmission electron microscopy; TI, thecal interstitial.

Received March 1, 2006.

Accepted for publication April 13, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Payne AH, Hales DB 2004 Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25:947–970[Abstract/Free Full Text]
  2. Penning TM 1997 Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 18:281–305[Abstract/Free Full Text]
  3. Mindnich R, Moller G, Adamski J 2004 The role of 17ß-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 218:7–20[CrossRef][Medline]
  4. Sha JA, Dudley K, Rajapaksha WR, O’Shaughnessy PJ 1997 Sequence of mouse 17ß-hydroxysteroid dehydrogenase type 3 cDNA and tissue distribution of the type 1 and type 3 isoform mRNAs. J Steroid Biochem Mol Biol 60:19–24[CrossRef][Medline]
  5. Tsai-Morris CH, Khanum A, Tang PZ, Dufau ML 1999 The rat 17ß-hydroxysteroid dehydrogenase type III: molecular cloning and gonadotropin regulation. Endocrinology 140:3534–3542[Abstract/Free Full Text]
  6. Baker PJ, Sha JH, O’Shaughnessy PJ 1997 Localisation and regulation of 17ß-hydroxysteroid dehydrogenase type 3 mRNA during development in the mouse testis. Mol Cell Endocrinol 133:127–133[CrossRef][Medline]
  7. Mustonen MV, Poutanen MH, Isomaa VV, Vihko PT, Vihko RK 1997 Cloning of mouse 17ß-hydroxysteroid dehydrogenase type 2, and analysing expression of the mRNAs for types 1, 2, 3, 4 and 5 in mouse embryos and adult tissues. Biochem J 325:199–205
  8. Strauss III JF, Hsueh AJW 2001 Ovarian hormone synthesis. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia: W. B. Saunders Co.; 2043–2052
  9. Huhtaniemi I, Toppari J 1995 Endocrine, paracrine and autocrine regulation of testicular steroidogenesis. Adv Exp Med Biol 377:33–54[Medline]
  10. Sheffield JW, O’Shaughnessy PJ 1988 Testicular steroid metabolism during development in the normal and hypogonadal mouse. J Endocrinol 119:257–264[Abstract/Free Full Text]
  11. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C 1985 The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 6:371–399[Abstract/Free Full Text]
  12. Magoffin DA 2002 The ovarian androgen-producing cells: a 2001 perspective. Rev Endocr Metab Disord 3:47–53[CrossRef][Medline]
  13. Zhang Y, Word RA, Fesmire S, Carr BR, Rainey WE 1996 Human ovarian expression of 17ß-hydroxysteroid dehydrogenase types 1, 2, and 3. J Clin Endocrinol Metab 81:3594–3598[Abstract]
  14. Abney TO 1999 The potential roles of estrogens in regulating Leydig cell development and function: a review. Steroids 64:610–617[CrossRef][Medline]
  15. Ge R-S, Shan L-X, Hardy MP 1996 Pubertal development of Leydig cells. In: Payne AH, Hardy MP, Russell LD, eds. The Leydig cell. Vienna, IL: Cache River Press; 159–173
  16. Couse JF, Yates MM, Walker VR, Korach KS 2003 Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) null mice reveals hypergonadism and endocrine sex reversal in females lacking ER{alpha} but not ERß. Mol Endocrinol 17:1039–1053[Abstract/Free Full Text]
  17. Britt KL, Stanton PG, Misso M, Simpson ER, Findlay JK 2004 The effects of estrogen on the expression of genes underlying the differentiation of somatic cells in the murine gonad. Endocrinology 145:3950–3960[Abstract/Free Full Text]
  18. Couse JF, Yates MM, Sanford R, Nyska A, Nilson JH, Korach KS 2004 Formation of cystic ovarian follicles associated with elevated luteinizing hormone requires estrogen receptor-ß. Endocrinology 145:4693–4702[Abstract/Free Full Text]
  19. Mason AJ, Hayflick JS, Zoeller RT, Young 3rd WS, Phillips HS, Nikolics K, Seeburg PH 1986 A deletion truncating the gonadotropin-releasing hormone gene is responsible for hypogonadism in the hpg mouse. Science 234:1366–1371[Abstract/Free Full Text]
  20. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
  21. Magoffin DA, Erickson GF 1982 Primary culture of differentiating ovarian androgen-producing cells in defined medium. J Biol Chem 257:4507–4513[Free Full Text]
  22. Poirier D 2003 Inhibitors of 17ß-hydroxysteroid dehydrogenases. Curr Med Chem 10:453–477[Medline]
  23. Wiebe RH, Morris CV 1983 Testosterone/androstenedione ratio in the evaluation of women with ovarian androgen excess. Obstet Gynecol 61:279–284[Medline]
  24. Nilson JH, Abbud RA, Keri RA, Quirk CC 2000 Chronic hypersecretion of luteinizing hormone in transgenic mice disrupts both ovarian and pituitary function, with some effects modified by the genetic background. Recent Prog Horm Res 55:69–89; discussion 89–91[Medline]
  25. O’Shaughnessy PJ 1991 Steroidogenic enzyme activity in the hypogonadal (hpg) mouse testis and effect of treatment with luteinizing hormone. J Steroid Biochem Mol Biol 39:921–928[CrossRef][Medline]
  26. O’Shaughnessy PJ, Bennett MK, Scott IS, Charlton HM 1992 Effects of FSH on Leydig cell morphology and function in the hypogonadal mouse. J Endocrinol 135:517–525[Abstract/Free Full Text]
  27. Scott IS, Charlton HM, Cox BS, Grocock CA, Sheffield JW, O’Shaughnessy PJ 1990 Effect of LH injections on testicular steroidogenesis, cholesterol side-chain cleavage P450 mRNA content and Leydig cell morphology in hypogonadal mice. J Endocrinol 125:131–138[Abstract/Free Full Text]
  28. Murono EP, Payne AH 1979 Testicular maturation in the rat. In vivo effect of gonadotropins on steroidogenic enzymes in the hypophysectomized immature rat. Biol Reprod 20:911–917[Abstract]
  29. Ghersevich S, Nokelainen P, Poutanen M, Orava M, Autio-Harmainen H, Rajaniemi H, Vihko R 1994 Rat 17ß-hydroxysteroid dehydrogenase type 1: primary structure and regulation of enzyme expression in rat ovary by diethylstilbestrol and gonadotropins in vivo. Endocrinology 135:1477–1487[Abstract]
  30. Ghersevich S, Poutanen M, Tapanainen J, Vihko R 1994 Hormonal regulation of rat 17ß-hydroxysteroid dehydrogenase type 1 in cultured rat granulosa cells: effects of recombinant follicle-stimulating hormone, estrogens, androgens, and epidermal growth factor. Endocrinology 135:1963–1971[Abstract]
  31. Russell LD 1996 Mammalian Leydig cell structure. In: Payne AH, Hardy MP, Russell LD, eds. The Leydig cell. Vienna, IL: Cache River Press; 43–96
  32. Dhar JD, Setty BS 1976 Epididymal response to exogenous testosterone in rats sterilized neonatally by estrogen. Endokrinologie 68:14–21[Medline]
  33. Abney TO, Myers RB 1991 17ß-Estradiol inhibition of Leydig cell regeneration in the ethane dimethylsulfonate-treated mature rat. J Androl 12:295–304[Abstract/Free Full Text]
  34. Risma KA, Clay CM, Nett TM, Wagner T, Yun J, Nilson JH 1995 Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci USA 92:1322–1326[Abstract/Free Full Text]
  35. Risma KA, Hirshfield AN, Nilson JH 1997 Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Endocrinology 138:3540–3547[Abstract/Free Full Text]
  36. Rulli SB, Kuorelahti A, Karaer O, Pelliniemi LJ, Poutanen M, Huhtaniemi I 2002 Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. Endocrinology 143:4084–4095[Abstract/Free Full Text]
  37. Matzuk MM, DeMayo FJ, Hadsell LA, Kumar TR 2003 Overexpression of human chorionic gonadotropin causes multiple reproductive defects in transgenic mice. Biol Reprod 69:338–346[Abstract/Free Full Text]
  38. Heikkilä M, Prunskaite R, Naillat F, Itaranta P, Vuoristo J, Leppaluoto J, Peltoketo H, Vainio S 2005 The partial female to male sex reversal in Wnt-4-deficient females involves induced expression of testosterone biosynthetic genes and testosterone production, and depends on androgen action. Endocrinology 146:4016–4023[CrossRef][Medline]
  39. Lau IF, Saksena SK, Chang MC 1978 Effects of hCG on serum levels of testosterone, dihydrotestosterone and androstenedione in male mice. Horm Res 9:169–175[CrossRef][Medline]
  40. Chandrashekar V, Bartke A, Awoniyi CA, Tsai-Morris CH, Dufau ML, Russell LD, Kopchick JJ 2001 Testicular endocrine function in GH receptor gene disrupted mice. Endocrinology 142:3443–3450[Abstract/Free Full Text]
  41. Allan CA, McLachlan RI 2001 Androgen deficiency syndrome. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia: W. B. Saunders Co.; 3159–3191
  42. Andersson S, Moghrabi N 1997 Physiology and molecular genetics of 17ß-hydroxysteroid dehydrogenases. Steroids 62:143–147[CrossRef][Medline]
  43. Peltoketo H, Vihko P, Vihko R 1999 Regulation of estrogen action: role of 17ß-hydroxysteroid dehydrogenases. Vitam Horm 55:353–398[Medline]
  44. Nokelainen P, Puranen T, Peltoketo H, Orava M, Vihko P, Vihko R 1996 Molecular cloning of mouse 17ß-hydroxysteroid dehydrogenase type 1 and characterization of enzyme activity. Eur J Biochem 236:482–490[Medline]
  45. Puranen T, Poutanen M, Ghosh D, Vihko R, Vihko P 1997 Origin of substrate specificity of human and rat 17ß-hydroxysteroid dehydrogenase type 1, using chimeric enzymes and site-directed substitutions. Endocrinology 138:3532–3539[Abstract/Free Full Text]
  46. Magoffin DA, Erickson GF 1982 Direct inhibitory effect of estrogen on LH-stimulated androgen synthesis by ovarian cells cultured in defined medium. Mol Cell Endocrinol 28:81–89[CrossRef][Medline]
  47. Zhou Q, Nie R, Prins GS, Saunders PT, Katzenellenbogen BS, Hess RA 2002 Localization of androgen and estrogen receptors in adult male mouse reproductive tract. J Androl 23:870–881[Abstract/Free Full Text]
  48. Pelletier G, Labrie C, Labrie F 2000 Localization of oestrogen receptor {alpha}, oestrogen receptor ß and androgen receptors in the rat reproductive organs. J Endocrinol 165:359–370[Abstract]
  49. Sar M, Welsch F 1999 Differential expression of estrogen receptor-ß and estrogen receptor-{alpha} in the rat ovary. Endocrinology 140:963–971[Abstract/Free Full Text]
  50. Saunders PTK, Maguire SM, Gaughan J, Millar MR 1997 Expression of oestrogen receptor ß (ERß) in multiple rat tissues visualized by immunohistochemistry. J Endocrinol 154:R13–R16
  51. Saunders PT, Millar MR, Williams K, Macpherson S, Harkiss D, Anderson RA, Orr B, Groome NP, Scobie G, Fraser HM 2000 Differential expression of estrogen receptor-{alpha} and -ß and androgen receptor in the ovaries of marmosets and humans. Biol Reprod 63:1098–1105[Abstract/Free Full Text]
  52. Papadopoulos V 1996 Pharmacologic influence on androgen biosynthesis. In: Payne AH, Hardy MP, Russell LD, eds. The Leydig cell. Vienna, IL: Cache River Press; 597–628
  53. Akingbemi BT, Ge R, Rosenfeld CS, Newton LG, Hardy DO, Catterall JF, Lubahn DB, Korach KS, Hardy MP 2003 Estrogen receptor-{alpha} gene deficiency enhances androgen biosynthesis in the mouse Leydig cell. Endocrinology 144:84–93[Abstract/Free Full Text]
  54. Schomberg DW, Couse JF, Mukherjee A, Lubahn DB, Sar M, Mayo KE, Korach KS 1999 Targeted disruption of the estrogen receptor-{alpha} gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology 140:2733–2744[Abstract/Free Full Text]
  55. Couse JF, Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20:358–417[Abstract/Free Full Text]
  56. Sternberg WH, Roth LM 1973 Ovarian stromal tumors containing Leydig cells: I. Stromal-Leydig cell tumor and non-neoplastic transformation of ovarian stroma to Leydig cells. Cancer 32:940–951[CrossRef][Medline]
  57. Roth LM, Sternberg WH 1973 Ovarian stromal tumors containing Leydig cells: II. Pure Leydig cell tumor, non-hilar type. Cancer 32:952–960[CrossRef][Medline]
  58. Bohm J, Roder-Weber M, Hofler H, Kolben M 1991 Bilateral stromal Leydig cell tumour of the ovary. Case report and literature review. Pathol Res Pract 187:348–352; discussion 352–353[Medline]
  59. Oler A, Singh M, Ural SH 1999 Bilateral ovarian stromal hyperplasia concealing a nonhilar, pure stromal-Leydig cell tumor. A case report. J Reprod Med 44:563–566[Medline]
  60. Barbieri RL 1992 Human ovarian 17-ketosteroid oxidoreductase: unique characteristics of the granulosa-luteal cell and stromal enzyme. Am J Obstet Gynecol 166:1117–1123; discussion 1123–1126[Medline]
  61. Haider SG, Pickartz H, Freundl G, Passia D 1985 Demonstration of hydroxysteroid dehydrogenases and testosterone in the Sertoli-Leydig cell tumor (androblastoma) tissue of the human ovary: an enzyme histochemical and immunohistochemical study. Acta Anat (Basel) 121:170–173[Medline]
  62. Ichinohasama R, Teshima S, Kishi K, Mukai K, Tsunematsu R, Ishii-Ohba H, Shimosato Y 1989 Leydig cell tumor of the ovary associated with endometrial carcinoma and containing 17ß-hydroxysteroid dehydrogenase. Int J Gynecol Pathol 8:64–71[Medline]
  63. Barbieri RL, Gao X 1997 Presence of 17ß-hydroxysteroid dehydrogenase type 3 messenger ribonucleic acid transcript in an ovarian Sertoli-Leydig cell tumor. Fertil Steril 68:534–537[CrossRef][Medline]
  64. Nelson VL, Legro RS, Strauss 3rd JF, McAllister JM 1999 Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 13:946–957[Abstract/Free Full Text]
  65. Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, Strauss 3rd JF, McAllister JM 2001 The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86:5925–5933[Abstract/Free Full Text]
  66. Diao FY, Xu M, Hu Y, Li J, Xu Z, Lin M, Wang L, Zhou Y, Zhou Z, Liu J, Sha J 2004 The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray. J Mol Endocrinol 33:59–72[Abstract]
  67. Couse JF, Hewitt SC, Korach KS 2006 Steroid receptors in the ovary and uterus. In: Neill JD, ed. Knobil and Neill’s physiology of reproduction. 3rd ed. San Diego and Oxford: Elsevier Science; 593–678
  68. Kaipia A, Hsueh AJ 1997 Regulation of ovarian follicle atresia. Annu Rev Physiol 59:349–363[CrossRef][Medline]
  69. Hsueh AJW, Billig H, Tsafriri 1994 Ovarian follicle atresia: a hormonally controlled apoptotic process. Endocr Rev 15:707–724[Abstract/Free Full Text]
  70. Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, Davis BJ, Korach KS 1999 Postnatal sex reversal of the ovaries in mice lacking estrogen receptors {alpha} and ß. Science 286:2328–2331[Abstract/Free Full Text]
  71. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M 2000 Effect of single and compound knockouts of estrogen receptors {alpha} (ER{alpha}) and ß (ERß) on mouse reproductive phenotypes. Development 127:4277–4291[Abstract]



This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
B. J. Deroo, K. F. Rodriguez, J. F. Couse, K. J. Hamilton, J. B. Collins, S. F. Grissom, and K. S. Korach
Estrogen Receptor {beta} Is Required for Optimal cAMP Production in Mouse Granulosa Cells
Mol. Endocrinol., July 1, 2009; 23(7): 955 - 965.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Strauss, J. Kallio, N. Desai, P. Pakarinen, T. Miettinen, H. Gylling, M. Albrecht, S. Makela, A. Mayerhofer, and M. Poutanen
Increased Exposure to Estrogens Disturbs Maturation, Steroidogenesis, and Cholesterol Homeostasis via Estrogen Receptor {alpha} in Adult Mouse Leydig Cells
Endocrinology, June 1, 2009; 150(6): 2865 - 2872.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
F. Taniguchi, J. F. Couse, K. F. Rodriguez, J. M. A. Emmen, D. Poirier, and K. S. Korach
Estrogen receptor-{alpha} mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17{alpha}-hydroxylase/17,20 lyase) expression
FASEB J, February 1, 2007; 21(2): 586 - 595.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Poutanen
Toward understanding the endocrine regulation of gonadal somatic cells.
Endocrinology, August 1, 2006; 147(8): 3662 - 3665.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Couse, J. F.
Right arrow Articles by Korach, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Couse, J. F.
Right arrow Articles by Korach, K. S.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*TESTOSTERONE

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals